Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
238.75 AUD | -0.15% |
|
-2.13% | -15.15% |
06-04 | Australia shares cross 8,500 as oil lifts energy stocks; tech, healthcare shine | RE |
05-23 | CSL Vifor Announces England's Nice Recommends Filspari®? as A Treatment Option for IgA Nephropathy | CI |
Capitalization | 75.66B 65.29B 61.36B 55.64B 103B 6,501B 116B 716B 279B 2,978B 284B 278B 10,903B | P/E ratio 2025 * |
25.6x | P/E ratio 2026 * | 22.3x |
---|---|---|---|---|---|
Enterprise value | 85.11B 73.44B 69.03B 62.6B 115B 7,313B 130B 805B 314B 3,350B 319B 313B 12,265B | EV / Sales 2025 * |
5.42x | EV / Sales 2026 * | 5.02x |
Free-Float |
99.9% | Yield 2025 * |
1.87% | Yield 2026 * | 2.07% |
More valuation ratios
* Estimated data
More news
Last Transcript: CSL Limited
More recommendations
More press releases
More news
1 day | +0.30% | ||
1 week | -1.77% | ||
Current month | -2.91% | ||
1 month | -0.83% | ||
3 months | -3.26% | ||
6 months | -13.36% | ||
Current year | -14.83% |
1 week | 237.66 | ![]() | 245.15 |
1 month | 237.66 | ![]() | 251.08 |
Current year | 228.61 | ![]() | 290.32 |
1 year | 228.61 | ![]() | 313.55 |
3 years | 228.61 | ![]() | 314.28 |
5 years | 228.61 | ![]() | 320.42 |
10 years | 85.4 | ![]() | 342.75 |
Manager | Title | Age | Since |
---|---|---|---|
Paul McKenzie
CEO | Chief Executive Officer | 59 | 05/03/2023 |
Mark Hill
CTO | Chief Tech/Sci/R&D Officer | 63 | 30/09/2020 |
Chief Tech/Sci/R&D Officer | 67 | 30/09/2018 |
Director | Title | Age | Since |
---|---|---|---|
Director/Board Member | 71 | 16/10/2018 | |
Marie McDonald
BRD | Director/Board Member | 69 | 13/08/2013 |
Megan Clark
BRD | Director/Board Member | 67 | 15/02/2016 |
Name | Weight | AuM | 1st Jan change | |
---|---|---|---|---|
2.91% | 21 M€ | +0.87% | - | |
2.49% | 7 M€ | +14.74% | - |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
+0.48% | -1.77% | -16.96% | -7.29% | 75.29B | ||
-0.39% | +1.50% | +37.72% | +28.48% | 53.15B | ||
-0.92% | -0.49% | +17.48% | +101.48% | 35.91B | ||
+0.30% | -1.57% | -43.44% | -33.57% | 19.14B | ||
-0.50% | +9.77% | +109.66% | +205.32% | 16.98B | ||
+5.19% | +10.04% | +53.02% | +952.11% | 15.1B | ||
-0.04% | -.--% | +94.58% | +133.27% | 14.02B | ||
+5.12% | +3.56% | +14.67% | +3.89% | 13.11B | ||
-2.20% | -12.17% | -4.63% | -32.48% | 11.47B | ||
+0.04% | -0.72% | -32.65% | -24.15% | 10.78B | ||
Average | +0.69% | +0.34% | +22.94% | +132.71% | 26.5B | |
Weighted average by Cap. | +0.33% | -0.24% | +16.23% | +87.23% |
2025 * | 2026 * | |
---|---|---|
Net sales | 15.7B 13.55B 12.73B 11.55B 21.29B 1,349B 24.03B 148B 57.87B 618B 58.91B 57.67B 2,262B | 16.69B 14.41B 13.54B 12.28B 22.64B 1,434B 25.55B 158B 61.54B 657B 62.63B 61.31B 2,406B |
Net income | 2.98B 2.57B 2.41B 2.19B 4.04B 256B 4.56B 28.15B 10.97B 117B 11.17B 10.93B 429B | 3.39B 2.93B 2.75B 2.5B 4.6B 292B 5.19B 32.1B 12.51B 134B 12.73B 12.47B 489B |
Net Debt | 9.45B 8.16B 7.67B 6.95B 12.82B 812B 14.47B 89.41B 34.85B 372B 35.47B 34.72B 1,362B | 8.14B 7.03B 6.6B 5.99B 11.04B 700B 12.46B 77.01B 30.01B 320B 30.55B 29.9B 1,173B |
More financial data
* Estimated data
Employees
32,698
Sector
Pharmaceuticals
Calendar
Date | Price | Change | Volume |
---|---|---|---|
17/06/25 | 238.75 $ | -0.15% | 228,675 |
16/06/25 | 239.10 $ | +0.10% | 386,113 |
13/06/25 | 238.86 $ | -0.91% | 723,664 |
12/06/25 | 241.05 $ | +0.08% | 622,476 |
11/06/25 | 240.85 $ | -1.34% | 501,001 |
Delayed Quote Australian S.E., June 17, 2025 at 01:38 am
More quotesSell
Buy

Mean consensus
BUY
Number of Analysts
17
Last Close Price
156.25USD
Average target price
202.35USD
Spread / Average Target
+29.50%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CSL Stock
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition